305 related articles for article (PubMed ID: 16249422)
1. The patents-based pharmaceutical development process: rationale, problems, and potential reforms.
Barton JH; Emanuel EJ
JAMA; 2005 Oct; 294(16):2075-82. PubMed ID: 16249422
[TBL] [Abstract][Full Text] [Related]
2. The ethics and economics of pharmaceutical pricing.
Parker-Lue S; Santoro M; Koski G
Annu Rev Pharmacol Toxicol; 2015; 55():191-206. PubMed ID: 25149920
[TBL] [Abstract][Full Text] [Related]
3. Patents for critical pharmaceuticals: the AZT case.
Ackiron E
Am J Law Med; 1991; 17(1-2):145-80. PubMed ID: 1877607
[TBL] [Abstract][Full Text] [Related]
4. Pharmaceuticals and medical devices: business practices.
Steiner DJ
Issue Brief Health Policy Track Serv; 2013 Dec; ():1-36. PubMed ID: 24482889
[No Abstract] [Full Text] [Related]
5. Realizing two-tiered innovation policy through drug regulation.
Ridgway WE
Stanford Law Rev; 2006 Feb; 58(4):1221-50. PubMed ID: 16685807
[No Abstract] [Full Text] [Related]
6. Asserting the primacy of health over patent rights: a comparative study of the processes that led to the use of compulsory licensing in Thailand and Brazil.
Rosenberg ST
Dev World Bioeth; 2014 Aug; 14(2):83-91. PubMed ID: 24750542
[TBL] [Abstract][Full Text] [Related]
7. An ethical dilemma. Patents & profits v. access & affordability.
Blasi AE
J Leg Med; 2012 Jan; 33(1):115-28. PubMed ID: 22439710
[No Abstract] [Full Text] [Related]
8. The global drug gap.
Reich MR
Science; 2000 Mar; 287(5460):1979-81. PubMed ID: 10755953
[TBL] [Abstract][Full Text] [Related]
9. Differential pricing for pharmaceuticals: reconciling access, R&D and patents.
Danzon PM; Towse A
Int J Health Care Finance Econ; 2003 Sep; 3(3):183-205. PubMed ID: 14625999
[TBL] [Abstract][Full Text] [Related]
10. Developing drugs for developing countries.
Ridley DB; Grabowski HG; Moe JL
Health Aff (Millwood); 2006; 25(2):313-24. PubMed ID: 16522573
[TBL] [Abstract][Full Text] [Related]
11. [An analysis of the pharmaceuticals market in Vietnam].
Simonet D
Sante; 2001; 11(3):155-60. PubMed ID: 11641078
[TBL] [Abstract][Full Text] [Related]
12. Repairing the broken market for antibiotic innovation.
Outterson K; Powers JH; Daniel GW; McClellan MB
Health Aff (Millwood); 2015 Feb; 34(2):277-85. PubMed ID: 25646108
[TBL] [Abstract][Full Text] [Related]
13. The information revolution reaches pharmaceuticals: balancing innovation incentives, cost, and access in the post-genomics era.
Rai AK
Univ Ill Law Rev; 2001; 2001(1):173-210. PubMed ID: 16493845
[TBL] [Abstract][Full Text] [Related]
14. Value of pharmaceuticals: ensuring the future of research and development.
Serajuddin HK; Serajuddin AT
J Am Pharm Assoc (2003); 2006; 46(4):511-6. PubMed ID: 16913396
[TBL] [Abstract][Full Text] [Related]
15. An economic justification for open access to essential medicine patents in developing countries.
Flynn S; Hollis A; Palmedo M
J Law Med Ethics; 2009; 37(2):184-208. PubMed ID: 19493066
[TBL] [Abstract][Full Text] [Related]
16. Revitalizing the patent system to incentivize pharmaceutical innovation: the potential of claims with means-plus-function clauses.
Tang WL
Duke Law J; 2013 Feb; 62(5):1069-108. PubMed ID: 25330553
[TBL] [Abstract][Full Text] [Related]
17. Does Increased Spending on Pharmaceutical Marketing Inhibit Pioneering Innovation?
Arnold DG; Troyer JL
J Health Polit Policy Law; 2016 Apr; 41(2):157-79. PubMed ID: 26732315
[TBL] [Abstract][Full Text] [Related]
18. Ownership of knowledge--the role of patents in pharmaceutical R&D.
Correa CM
Bull World Health Organ; 2004 Oct; 82(10):784-7; discussion 787-90. PubMed ID: 15643801
[TBL] [Abstract][Full Text] [Related]
19. Potential pathways for abbreviated approval of generic biologics under existing law and proposed reforms to the law.
Dinh TQ
Food Drug Law J; 2007; 62(1):77-137. PubMed ID: 17444027
[No Abstract] [Full Text] [Related]
20. Economics of new oncology drug development.
DiMasi JA; Grabowski HG
J Clin Oncol; 2007 Jan; 25(2):209-16. PubMed ID: 17210942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
